Abstract
The purpose of this study was to examine the relationship between mood and hormonal responses to cholinergic challenge with physostigmine in order to assess cholinergic system responsiveness in borderline personality disorder (BPD) patients, other non-BPD personality disorder patients, and normal controls. Thirty-four personality disorder patients, 10 of whom met criteria for BPD and 24 of whom met criteria for other, non-borderline, personality disorders, and 11 normal controls participated in a double blind, placebo controlled physostigmine challenge paradigm. The Profile of Mood States depression subscale (POMS-D) self report measure was obtained at baseline and following the physostigmine or placebo infusions. A repeated measures ANOVA of POMS-D scores in placebo and drug conditions indicated a significantly greater depressive response in the total cohort of personality disorder patients than in the normal comparison group (p < 0.05). However, the depressive response to physostigmine was significantly greater in BPD patients, but not other personality disorder patients, compared to normal controls (p < 0.05). There was a correlation between the peak placebo-corrected depressive response to physostigmine and a group of BPD traits related to affective instability but not a group of BPD traits related to impulsivity. There was no correlation in any group between mood response to physostigmine and changes in plasma cortisol, prolactin, or growth hormone, or to nausea or other side effects following physostigmine infusion. These data suggest that there is an association between BPD and acute depressive responses to physostigmine challenge, and that the cholinergic system may be involved in the regulation of affect in Axis II disorders.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steinberg, B., Trestman, R., Mitropoulou, V. et al. Depressive Response to Physostigmine Challenge in Borderline Personality Disorder Patients. Neuropsychopharmacol 17, 264–273 (1997). https://doi.org/10.1016/S0893-133X(97)00051-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/S0893-133X(97)00051-1
Keywords
This article is cited by
-
Associations of Acetylcholinesterase Inhibition Between Pesticide Spray Seasons with Depression and Anxiety Symptoms in Adolescents, and the Role of Sex and Adrenal Hormones on Gender Moderation
Exposure and Health (2021)
-
Remediation and Cognitive Enhancers in Schizotypal Personality Disorder
Current Treatment Options in Psychiatry (2014)
-
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Neuropsychopharmacology (2012)
-
Validation of the Immediate and Delayed Memory Tasks in Hospitalized Adolescents with Disruptive Behavior Disorders
The Psychological Record (2003)
-
Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents
Current Psychiatry Reports (2000)